

FORM PTO1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANT Edward T. Wei	
		FILED September 11, 2003	GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	Class	Sub Class	Filing Date
	A1	4 0 7 0 4 9 6	1/24/78	Rowsell and Spring		
	A2	5 5 8 2 3 3 0	12/28/94	Iba		
	A3					
	A4					
	A5					
	A6					
	A7					
	A8					
	A9					
	A10					

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	Class	Sub Class	Trans? (Yes/No)
B1					
B2					
B3					
B4					
B5					

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent pages, etc.)*

C1	Code of Federal Regulations, Section 21 Part 349, Ch. 1(4-1-01 Edition). pg. 270 to 275. Ophthalmic Drug Products for Over-the Counter Human Use.
C2	G. Hecht, Ophthalmic Solutions, Chapt 43, pg. 821-835, in "Remington, the Science and Practice of Pharmacy," Alfonso R. Gennaro, Editor. 20th ed. Baltimore, Md.: Lippincott Williams & Wilkins, 2000.
C3	H.R. Watson, R. Hems, D.G. Rowsell and D.J. Spring. New Compounds with the Menthol Cooling Effect. Journal of the Society of Cosmetic Chemistry. 29: 185-200, 1978.

EXAMINER	DATE CONSIDERED
-----------------	------------------------

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.